LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Open

SectorHealthcare

21.14 1

Buy Sell

Overview

Share price change

24h

Current

Min

20.37

Max

21.25

Key metrics
By Trading Economics
Income	-270M 3.6M
Sales	-16M 268M
P/E Sector Avg	9.362 49.701
EPS	0.02
Profit margin	1.357
Employees	796
EBITDA	-31M -4.6M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+56.42% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-256M 3.5B
Previous open	20.14
Previous close	21.14

News Sentiment

By Acuity

50%

159 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

14.845 / N/A Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 May 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 May 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 May 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 May 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 May 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 May 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 May 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 May 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 May 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 May 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 May 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 May 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 May 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 May 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 May 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 May 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 May 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 May 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 May 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 May 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 May 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 May 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 May 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 May 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 May 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 May 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 May 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 May 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

56.42% upside

12 Months Forecast

Average 32.77 USD 56.42%

High 38 USD

Low 24 USD

Based on 15 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

159 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.